Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.
EAI
Show more
Clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for testing biopsy and other tissue samples for use in disease detection, namely, breast cancer; clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for breast cancer surveillance, namely, for measuring amounts of genomic and other biomarkers contacted with the reagent, such as estrogen receptor (ER), progesterone receptor (PR) associated biomarkers, and other suitable biomarkers for monitoring breast cancer occurrence, recurrence, response to various chemotherapies, hormone therapies, radiation therapies, or other suitable treatments
Class 5 – Pharmaceuticals & supplements
Status timeline
- 10 Aug 2023Application filedNew Application Entered
- 8 Apr 2024Assigned to an examining attorneyAssigned To Examiner
- 11 Apr 2024Office action issuedNon-Final Action Written
- 19 Apr 2024Response to office action filedTeas Response To Office Action Received
- 20 Apr 2024Final refusal issuedFinal Refusal Mailed
- 12 Sep 2024Approved for publicationApproved For Pub - Principal Register
- 22 Oct 2024Published for oppositionPublished For Opposition
- 3 Dec 2024Notice of allowance issued — statement of use requiredNoa Mailed - Sou Required From Applicant
- 3 Jun 2025Statement of use filedTeas Statement Of Use Received
- 26 Nov 2025Statement of use acceptedAllowed Principal Register - Sou Accepted
- 16 Dec 2025Registered on the Principal RegisterRegistered-Principal Register
All 32 events
| 2025-12-16 | Registered-Principal Register |
| 2025-12-16 | Notice Of Registration Confirmation Emailed |
| 2025-11-26 | Allowed Principal Register - Sou Accepted |
| 2025-11-26 | Notice Of Acceptance Of Statement Of Use E-Mailed |
| 2025-11-22 | Case Assigned To Intent To Use Paralegal |
| 2025-11-22 | Statement Of Use Processing Complete |
| 2025-06-03 | Teas Statement Of Use Received |
| 2025-06-03 | Use Amendment Filed |
| 2024-12-03 | Noa Mailed - Sou Required From Applicant |
| 2024-10-22 | Published For Opposition |
| 2024-10-22 | Official Gazette Publication Confirmation E-Mailed |
| 2024-10-02 | Notification Of Notice Of Publication E-Mailed |
| 2024-09-12 | Assigned To Lie |
| 2024-09-12 | Correspondence Received In Law Office |
| 2024-09-12 | Teas/Email Correspondence Entered |
| 2024-09-12 | Approved For Pub - Principal Register |
| 2024-04-23 | Teas Request For Reconsideration Received |
| 2024-04-20 | Final Refusal Mailed |
| 2024-04-20 | Final Refusal E-Mailed |
| 2024-04-20 | Notification Of Final Refusal Emailed |
| 2024-04-19 | Teas Response To Office Action Received |
| 2024-04-19 | Correspondence Received In Law Office |
| 2024-04-19 | Teas/Email Correspondence Entered |
| 2024-04-11 | Non-Final Action Written |
| 2024-04-11 | Non-Final Action E-Mailed |
| 2024-04-11 | Notification Of Non-Final Action E-Mailed |
| 2024-04-08 | Assigned To Examiner |
| 2024-02-12 | Teas Revoke/App/Change Addr Of Atty/Dom Rep Received |
| 2024-02-12 | Attorney/Dom.rep.revoked And/Or Appointed |
| 2024-02-12 | Teas Change Of Correspondence Received |
| 2023-09-06 | New Application Office Supplied Data Entered |
| 2023-08-10 | New Application Entered |
Goods & services by class
Class 5 Pharmaceuticals & supplements
Clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for testing biopsy and other tissue samples for use in disease detection, namely, breast cancer; clinical diagnostic testing kits comprised of medical diagnostic reagents and assays for breast cancer surveillance, namely, for measuring amounts of genomic and other biomarkers contacted with the reagent, such as estrogen receptor (ER), progesterone receptor (PR) associated biomarkers, and other suitable biomarkers for monitoring breast cancer occurrence, recurrence, response to various chemotherapies, hormone therapies, radiation therapies, or other suitable treatments
First use anywhere 3 Dec 2023 · First use in commerce 3 Dec 2023
Owner details
See the official record for contact details. View official record →
Source & freshness
Source: the official United States trademark register. This record was last updated on 16 Dec 2025; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.